Jefferies Financial Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Jefferies Financial Group's NBIX Position: Q3 2026 in Review
Jefferies Financial Group sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 10,630 shares — an estimated $1.79M sold.
Jefferies Financial Group first reported a position in NBIX in Q4 2022 and held it in 9 quarters. The position peaked at $6.52M in Q4 2025. 770 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Jefferies Financial Group reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
- Jefferies Financial Group sold 10,630 Neurocrine Biosciences shares in Q3 2026, an estimated $1.79M.
- Jefferies Financial Group first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 9 quarters.
- Jefferies Financial Group's Neurocrine Biosciences position peaked at $6.52M in Q4 2025.
- 770 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Jefferies Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.